ProfileGDS5678 / 1416570_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 81% 82% 83% 81% 83% 83% 82% 81% 81% 81% 82% 83% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.9071282
GSM967853U87-EV human glioblastoma xenograft - Control 25.8979581
GSM967854U87-EV human glioblastoma xenograft - Control 35.8962282
GSM967855U87-EV human glioblastoma xenograft - Control 46.2626683
GSM967856U87-EV human glioblastoma xenograft - Control 55.7835581
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.89683
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8896583
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.8744582
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.8218181
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.811581
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.8010181
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.0364482
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.0450683
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.8502482